Development and Validation of HPLC-UV Method for the Determination of a Potent Synthetic Cannabinoid THJ-2201 in Mouse Plasma and Application in a Pharmacokinetic Study

Author(s): Hassan Y. Aboul-Enein*, Gamal A.E Mostafa*, Haitham AlRabiah, Mohammed Al-Ramadi, Sabry M. Attia, Hebatallah A. Wagdy

Journal Name: Current Pharmaceutical Analysis

Volume 16 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Aim: A new simple and sensitive high-Performance Liquid Chromatography (HPLC) method for the determination of a potent synthetic cannabinoid THJ-2201, has been developed and validated. Lixiviptan was used as the Internal Standard (IS).

Methods: THJ-2201 and IS were extracted from mouse plasma using deproteinization procedure that uses acetonitrile followed by HPLC analysis. The separation was carried out on a reversed-phase C18 column using water and acetonitrile mixture (30:70 v/v). The flow-rate was 1.0 mL/min. Eluting of both THJ-2201 and lixivaptan was performed at 220 nm.

Results: The method demonstrated linearity over a calibration range of 95 - 1500 ng/mL and the Limit of Detection (LOD) and Quantitation (LOQ) were 28 ng/mL and 91 ng/mL, respectively. The validation of the proposed method was carried out by following the US Food and Drug Administration (FDA) guidelines. Intra- and inter-day precision did not exceed 6.4%, whereas the accuracy of THJ-2201 measurements was within ±13%.

Conclusion: This new method is simple and sensitive and has been applied successfully in a pharmacokinetic study of THJ-2201 in mouse plasma. The mean values of Tmax and Cmax were 0.25 h and 141.87 ± 12.11 ng/mL, respectively.

Keywords: THJ-2201, HPLC, validation, mouse plasma, pharmacokinetic study, synthetic cannabinoid.

[1]
Diao, X.; Wohlfarth, A.; Pang, S.; Scheidweiler, K.B.; Huestis, M.A. High resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoid thj-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin. Chem., 2016, 62(1), 157-169.
[http://dx.doi.org/10.1373/clinchem.2015.243535] [PMID: 26430074]
[2]
Shevyrin, V.; Melkozerov, V.; Nevero, A.; Eltsov, O.; Morzherin, Y.; Shafran, Y. 3-Naphthoylindazoles and 2-naphthoylbenzoimidazoles as novel chemical groups of synthetic cannabinoids: chemical structure elucidation, analytical characteristics and identification of the first representatives in smoke mixtures. Forensic Sci. Int., 2014, 242, 72-80.
[http://dx.doi.org/10.1016/j.forsciint.2014.06.022] [PMID: 25036783]
[3]
Uchiyama, N.; Shimokawa, Y.; Kawamura, M.; Kikura-Hanajiri, R.; Hakamatsuka, T. Chemical analysis of a benzofuran derivative, 2-(2-ethylaminopropyl)benzofuran (2-EAPB), eight synthetic cannabinoids, five cathinone derivatives, and five other designer drugs newly detected in illegal products. Forensic Toxicol., 2014, 32(2), 266-281.
[http://dx.doi.org/10.1007/s11419-014-0238-5]
[4]
Karila, L.; Benyamina, A.; Blecha, L.; Cottencin, O.; Billieux, J. The synthetic cannabinoids phenomenon. Curr. Pharm. Des., 2016, 22(42), 6420-6425.
[http://dx.doi.org/10.2174/1381612822666160919093450] [PMID: 27655416]
[5]
Hermanns-Clausen, M.; Kneisel, S.; Szabo, B.; Auwärter, V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction, 2013, 108(3), 534-544.
[http://dx.doi.org/10.1111/j.1360-0443.2012.04078.x] [PMID: 22971158]
[6]
Seely, K.A.; Lapoint, J.; Moran, J.H.; Fattore, L. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 39(2), 234-243.
[http://dx.doi.org/10.1016/j.pnpbp.2012.04.017] [PMID: 22561602]
[7]
Hess, C.; Stockhausen, S.; Kernbach-Wighton, G.; Madea, B. Death due to diabetic ketoacidosis: Induction by the consumption of synthetic cannabinoids? Forensic Sci. Int., 2015, 257, e6-e11.
[http://dx.doi.org/10.1016/j.forsciint.2015.08.012] [PMID: 26363623]
[8]
Koppel, B.S.; Brust, J.C.M.; Fife, T.; Bronstein, J.; Youssof, S.; Gronseth, G.; Gloss, D. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2014, 82(17), 1556-1563.
[http://dx.doi.org/10.1212/WNL.0000000000000363] [PMID: 24778283]
[9]
Sarfaraz, S.; Adhami, V.M.; Syed, D.N.; Afaq, F.; Mukhtar, H. Cannabinoids for cancer treatment: progress and promise. Cancer Res., 2008, 68(2), 339-342.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-2785] [PMID: 18199524]
[10]
Wolff, K.; Brimblecombe, R.; Forfar, J.C.; Forrest, A.R.; Gilvarry, E.; Johnston, A.; Morgan, J.; Osselton, M.D.; Read, L.; Taylor, D. Driving under the influence of drugs., 2013.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/167971/drug-driving-expert-panel-report.pdf
[11]
Fergusson, D.M.; Horwood, L.J.; Boden, J.M. Is driving under the influence of cannabis becoming a greater risk to driver safety than drink driving? Findings from a longitudinal study. Accid. Anal. Prev., 2008, 40(4), 1345-1350.
[http://dx.doi.org/10.1016/j.aap.2008.02.005] [PMID: 18606265]
[12]
Vikingsson, S.; Gréen, H. Putting designer drugs back in pandora’s box: Analytical challenges and metabolite identification. Clin. Chem., 2016, 62(1), 4-5.
[http://dx.doi.org/10.1373/clinchem.2015.248096] [PMID: 26546634]
[13]
Lang, J.R.; Bolton, S. A comprehensive method validation strategy for bioanalytical applications in the pharmaceutical industry--1. Experimental considerations. J. Pharm. Biomed. Anal., 1991, 9(5), 357-361.
[http://dx.doi.org/10.1016/0731-7085(91)80159-7] [PMID: 1932270]
[14]
González, O.; Blanco, M.E.; Iriarte, G.; Bartolomé, L.; Maguregui, M.I.; Alonso, R.M. Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect. J. Chromatogr. A, 2014, 1353(1), 10-27.
[http://dx.doi.org/10.1016/j.chroma.2014.03.077] [PMID: 24794936]
[15]
Waiver of. In vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification. System Guidance for Industry, 2014.http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
[16]
Gatch, M.B.; Forster, M.J.Δ. Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats. Psychopharmacology (Berl.), 2016, 233(10), 1901-1910.
[http://dx.doi.org/10.1007/s00213-016-4237-6] [PMID: 26875756]
[17]
Pucci, V.; Bugamelli, F.; Mandrioli, R.; Ferranti, A.; Kenndler, E.; Raggi, M.A. High-performance liquid chromatographic determination of Levetiracetam in human plasma: comparison of different sample clean-up procedures. Biomed. Chromatogr., 2004, 18(1), 37-44.
[http://dx.doi.org/10.1002/bmc.289] [PMID: 14872547]
[18]
Miller, J.N.; Miller, J.C. Statistics and Chemometrics for Analytical Chemistry, Sixth Edition;; Weston, P., Ed.; Limited, Essex CM20 2JE: England,, 2010.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 4
Year: 2020
Page: [404 - 411]
Pages: 8
DOI: 10.2174/1573412915666190204144843
Price: $65

Article Metrics

PDF: 26
HTML: 2